{"product_id":"eypt-bcg-matrix","title":"(EYPT) EyePoint Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis EyePoint Pharmaceuticals, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already includes a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo true 2025 star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals had no true 2025 BCG \"star\": its end-2025 mix was still built around niche commercial labels, while the main growth engine, EYP-1901, was still in development. With no product showing both high share and high growth at company scale, the star bucket stayed empty.\u003c\/p\u003e\n\u003cp\u003eThat matters because EyePoint’s 2025 revenue base was still modest and concentrated, so the next star has to be built first, not harvested yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEYP-1901 2x-yearly depot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEYP-1901 is EyePoint Pharmaceuticals, Inc.’s flagship late-stage asset and the clearest path to star status. Its twice-yearly depot is built for large retinal markets like wet AMD, which affects about 1.5 million people in the U.S.\u003c\/p\u003e\n\u003cp\u003eIf Phase 2 data keeps holding, it can shift from question mark to growth engine. Investors watch it as the main long-term value driver because fewer injections could improve use and adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWet age-related macular degeneration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWet age-related macular degeneration is a large, high-value market, with anti-VEGF therapy still driving millions of injections each year in the United States alone. EyePoint Pharmaceuticals, Inc. is developing EYP-1901 here because sustained delivery could cut treatment burden from frequent monthly dosing, and that fits a high-growth BCG Stars profile if durability and vision gains hold.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiabetic retinopathy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiabetic retinopathy is a large, under-treated retina market, with about 9.6 million Americans living with the disease and a growing diabetes base. A long-acting injectable or implantable therapy fits this use case because it can cut treatment burden and improve adherence. EyePoint is using EYP-1901 to target this need, and the addressable market is far bigger than EyePoint Pharmaceuticals, Inc.'s current commercial base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge unmet retina need\u003c\/li\u003e\n\u003cli\u003eLong-acting dosing is a fit\u003c\/li\u003e\n\u003cli\u003eEYP-1901 supports expansion\u003c\/li\u003e\n\u003cli\u003eMarket exceeds current scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetinal vein occlusion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetinal vein occlusion is a large retina use case, and it still needs repeat anti-VEGF injections, so the addressable demand stays meaningful. For EyePoint Pharmaceuticals, Inc., it fits the sustained-release thesis because a long-acting option could reduce treatment burden and plug into the same delivery platform. If late-stage data hold up, this could become a second growth leg with star-like upside in a market where retina drugs already generate billions in annual sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, repeat-treatment retina market\u003c\/li\u003e\n\u003cli\u003eMatches sustained-release strategy\u003c\/li\u003e\n\u003cli\u003eCould add a new growth leg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEYP-1901: EyePoint’s Retina Wild Card\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEYP-1901 is EyePoint Pharmaceuticals, Inc.'s only real Star candidate, but in 2025 it was still a Question Mark, not a Star. Its appeal is big retina markets like wet AMD, where the U.S. has about 1.5 million patients and repeat anti-VEGF care stays heavy. If Phase 2 data hold, its long-acting dosing could drive future growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 BCG view\u003c\/th\u003e\n\u003cth\u003eMarket signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eEYP-1901\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eWet AMD 1.5M U.S. patients\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEyePoint Pharmaceuticals’ BCG Matrix maps its pipeline and commercial assets into Stars, Cash Cows, Question Marks, and Dogs for capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly maps EyePoint Pharmaceuticals, Inc. BCG Matrix quadrants for a clean, presentation-ready view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for EyePoint Pharmaceuticals, Inc., helping users verify key claims and make faster, more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eILUVIEN 0.19 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eILUVIEN 0.19 mg is EyePoint Pharmaceuticals' mature fluocinolone acetonide implant for diabetic macular edema. Its 0.19 mg dose can deliver drug for up to 36 months, supporting repeat specialty use from a defined retina-physician base. That steady, recurring demand is classic cash-cow behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYUTIQ 0.18 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYUTIQ 0.18 mg is EyePoint Pharmaceuticals, Inc.'s approved sustained-release fluocinolone implant for chronic non-infectious uveitis of the posterior segment. It serves a niche, repeat-use specialty market and has been commercialized since 2018, so it brings steady legacy revenue. That makes it a high-share, low-growth cash cow that helps fund EyePoint Pharmaceuticals, Inc.'s wider pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty retina revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. keeps specialty retina revenue in a cash-cow role: a small branded base, led by YUTIQ, can keep producing cash while the company directs heavy R\u0026amp;D into its pipeline. That matters because the marketed ophthalmology labels do not need the same spend as EYP-1901, so operating cash is more about harvest than fast growth. In FY2025, this kind of stable, low-capex revenue helps fund development without leaning fully on new equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLong-acting implant economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eILUVIEN and YUTIQ use sustained-release implants, so EyePoint Pharmaceuticals, Inc. can charge premium specialty prices and cut repeat dosing. Longer drug duration also helps physician workflow and patient adherence, which usually lifts gross economics versus short-course acute eye drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium sustained-release pricing\u003c\/li\u003e\n\u003cli\u003eBetter adherence and convenience\u003c\/li\u003e\n\u003cli\u003eHigher gross margin mix\u003c\/li\u003e\n\u003cli\u003eCore cash source from mature implants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes long-acting implant economics a steady cash cow for EyePoint Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-supported sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses partner channels to extend reach without funding a large direct force, which keeps selling costs tighter and supports better cash conversion from mature brands. That fits a Cash Cow profile: limited new growth, but steady value from existing assets. In the latest reported periods, this model helped offset the high cost of building full commercial coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower SG\u0026amp;A burden\u003c\/li\u003e\n\u003cli\u003eBroader market access\u003c\/li\u003e\n\u003cli\u003eSteadier cash from legacy brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint’s Retina Implants Are Steady Cash Cows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eILUVIEN and YUTIQ are EyePoint Pharmaceuticals, Inc.’s Cash Cows: mature, niche retina implants with repeat specialty use and steady legacy demand. ILUVIEN can deliver up to 36 months, and YUTIQ has been commercialized since 2018, so both fit low-growth, cash-generating assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eILUVIEN\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eUp to 36 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYUTIQ\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eCommercialized since 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eEyePoint Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis EyePoint Pharmaceuticals, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the full, ready-to-use report. What you see here is what will be delivered instantly for your strategic review, editing, or presentation needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXYCU 9% suspension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXYCU 9% suspension is EyePoint Pharmaceuticals, Inc.’s clearest Dog: a one-time dexamethasone intraocular suspension for post-cataract inflammation in a crowded, price-sensitive market. Share gains are hard when many steroid options compete on cost, access, and physician habit. Its 9% formulation is a niche product, not a broad growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-cataract inflammation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePost-cataract inflammation is a large, routine care market, but it is dominated by entrenched steroid and NSAID standards. EyePoint Pharmaceuticals, Inc. has not turned this use case into a major growth driver in 2025-2026, so the segment needs selling effort but offers only modest return. That weak growth and low strategic pull place it in the dog bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-penetration commercial tail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.'s low-penetration commercial tail still fits the dog bucket: the smaller ophthalmology sales add activity, but not enough scale to shift results. These tails can consume selling and support time while generating weak capital efficiency. In FY2025, that means limited upside versus the cost of keeping them in the field.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh-competition steroid space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTopical and perioperative steroid care is a mature, crowded market, with about 4 million U.S. cataract surgeries a year and many low-cost generic options. EyePoint does not control category pricing, so competitors cap margins and limit share gains. That makes this a Dogs segment: weak pricing power, thin expansion, and hard-to-defend growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature steroid market\u003c\/li\u003e\n\u003cli\u003eGenerics cap pricing\u003c\/li\u003e\n\u003cli\u003eEyePoint lacks category control\u003c\/li\u003e\n\u003cli\u003eMargin and share upside limited\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited organic growth visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.’s older commercial labels, YUTIQ and DEXYCU, show limited organic growth visibility because they serve niche eye-care markets with little room for major volume acceleration. In 2024, total revenue was $47.8 million, while the company’s growth case shifted to pipeline assets like EYP-1901, not legacy products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy lines have weak expansion\u003c\/li\u003e\n\u003cli\u003ePipeline drives the equity story\u003c\/li\u003e\n\u003cli\u003eStagnation fits the dog label\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint’s Legacy Eye Drugs Stay in the Dog Bucket\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDEXYCU and YUTIQ stay in the Dog bucket for EyePoint Pharmaceuticals, Inc. in FY2025: they are niche, mature eye-care products with weak pricing power and little growth. EyePoint Pharmaceuticals, Inc. reported $47.8 million revenue in 2024, but the value story now sits with pipeline assets, not legacy sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog assets\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eDEXYCU\/YUTIQ\u003c\/td\u003e\n\u003ctd\u003eLow growth, crowded market\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue $47.8M\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYUTIQ50\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYUTIQ50 is EyePoint Pharmaceuticals, Inc.'s next-step program for chronic non-infectious uveitis in the posterior segment, building on the approved YUTIQ platform that delivers 0.18 mg fluocinolone acetonide for up to 36 months. The market is known, but YUTIQ50 still lacks clear commercial proof. At end-2025, it remains a Question Mark until adoption, prescribing, and revenue traction are visible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEYP-1901 wet AMD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEYP-1901 wet AMD is EyePoint Pharmaceuticals, Inc.'s biggest upside program, but it is still pre-commercial, so it fits the Question Mark box. Wet AMD affects about 20 million people worldwide and the anti-VEGF retina market remains a multibillion-dollar space, but EYP-1901 still has to clear clinical, regulatory, and launch steps. If it works, the payoff could be large; if not, the upside stays optional.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEYP-1901 diabetic retinopathy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEYP-1901 in diabetic retinopathy sits in a large unmet market: about 589 million adults live with diabetes worldwide, and roughly 1 in 3 develop retinopathy, or near 100 million people. EyePoint has no proven share yet, so the commercial case is still untested. If the delivery profile holds up, the program could scale fast; until then, it is a high-risk, high-reward bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEYP-1901 retinal vein occlusion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEYP-1901 retinal vein occlusion extends EyePoint Pharmaceuticals, Inc.'s same sustained-release retina platform into a large unmet-need area; retinal vein occlusion affects about 16 million people worldwide, but EYP-1901 has no established market share yet. If development succeeds, it could improve the mix away from a single-asset story. For now, it is still a question mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge addressable retina market\u003c\/li\u003e\n\u003cli\u003eNo proven share yet\u003c\/li\u003e\n\u003cli\u003eUpside depends on clinical success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTwice-yearly bioerodible TKI platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.'s twice-yearly bioerodible TKI platform is a classic question mark: it could build a differentiated franchise if long-duration efficacy and safety hold, but it still carries clinical and regulatory risk. The bet centers on EYP-1901, a pre-revenue asset aimed at replacing frequent injections with 2 doses a year. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upside if durability is proven\u003c\/li\u003e\n\u003cli\u003eRisk stays high until late-stage data\u003c\/li\u003e\n\u003cli\u003eTwice-yearly dosing is the edge\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint’s High-Upside Retina Bets Still Need Commercial Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.'s Question Marks are led by EYP-1901 and YUTIQ50: both target large retina markets, but neither has proven commercial share yet. EYP-1901 spans wet AMD, diabetic retinopathy, and RVO, with major upside tied to clinical and regulatory success. YUTIQ50 adds platform depth, but adoption and revenue traction are still untested.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEYP-1901\u003c\/td\u003e\n\u003ctd\u003ePre-commercial\u003c\/td\u003e\n\u003ctd\u003eHigh upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYUTIQ50\u003c\/td\u003e\n\u003ctd\u003eEarly launch\u003c\/td\u003e\n\u003ctd\u003eUnproven demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234278514953,"sku":"eypt-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/eypt-bcg-matrix.webp?v=1785718347","url":"https:\/\/dcfanalyst.com\/products\/eypt-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}